

October 18, 2023

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor,  
Plot No. C-1, G- Block,  
Bandra - Kurla Complex, Bandra (East)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

**Sub: Press Release - Financial Results**

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023.


Kindly take the above on record.

Thanking you,

Yours Sincerely,  
For RPG Life Sciences Limited

**RAJESH RAMESH SHIRAMBEKAR**  
Digitally signed by RAJESH  
RAMESH SHIRAMBEKAR  
Date: 2023.10.18 19:52:33 +05'30'

Rajesh Shirambekar  
Head – Legal & Company Secretary



Encl.: as above



**Q2 FY24 Revenue from operations grew by 14% Y-o-Y and 4% Q-o-Q.  
PBT grew by 29% Y-o-Y and 17% Q-o-Q.**

**Mumbai, 18 October, 2023:** RPG Life Sciences Limited has announced its financial results for the second quarter and half year ended September 30, 2023.

	<b>Y-o-Y Revenue from operations</b>	<b>Y-o-Y PBT</b>
Q2 FY24 Highlights	Rs 153.58 crores – up from Rs 134.79 crores	Rs 34.79 crores – up from Rs 27.01 crores
H1 FY24 Highlights	Rs 301.36 crores – up from Rs 263.72 crores	Rs 64.56 crores – up from Rs 52.13 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 29% Y-o-Y and by 17% Q-o-Q for Q2 FY24, maintaining the upward trajectory in EBITDA margins, which improved from 23.0% to 25.5% Y-o-Y and Q-o-Q. Revenue from operations at Rs 153.58 crores registered a growth of 14% Y-o-Y and a growth of 4% Q-o-Q for Q2 FY24. For H1 FY24 too, the company posted a jump in PBT by 29% Y-o-Y and recorded EBITDA margin expansion from 22.8% to 24.3% Y-o-Y. Revenue from operations at Rs 301.36 crores registered a growth of 14% Y-o-Y for H1 FY24.

**Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd.** said, “In Q2 FY24, the overall performance of the Company continued to be strong. Revenue and PBT grew by 14% and 29% respectively Y-o-Y. EBITDA margin retained its 5-year long upward trajectory growing from 23.0% to 25.5% Y-o-Y. The Company continues to remain debt-free.

Domestic Formulations business, the biggest contributor to the Company’s business, recorded robust growth both in value and volume - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth and become bigger brands, our new product portfolio comprising of newer and progressive segments is also shaping new therapies and product portfolio. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Salesforce productivity continues to register healthy upward momentum.

International Formulations business has also shown robust growth while emerging as another growth driver for the Company, registering healthy growth in both sales and profits. API business also registered healthy growth and improvement in margin. The Company is investing in plant modernization and capacity expansion in both plants as well as working on building a healthy product pipeline to accelerate exports of both formulations and API. Our relentless focus on achieving cost efficiencies in our operations, and eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals.”

**RPG Life Sciences Ltd ([www.rpglifesciences.com](http://www.rpglifesciences.com)):**

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

**RPG Group ([www.rpggroup.com](http://www.rpggroup.com)):**

RPG Group, established in 1979, is one of India’s fastest growing business groups with a turnover of US\$ 4.4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

**Media Contact:**

Shalini Singh – 92233 36815 | [shalini@rpg.in](mailto:shalini@rpg.in)  
Svati Maddur – 99208 87227 | [svati@rpg.in](mailto:svati@rpg.in)

